EUVIMEDOpdag EUVIMED
Video/Audio

Synergistic Neuroprotective Effects of Traditional Chinese Medicine and Levodopa in Parkinson's Disease: A Behavioral and Pharmacokinetic Study

Wei Nie, Ling Li

Journal of Visualized Experiments · 2025

DOI: 10.3791/69260 ↗

At a glance

Video/Audio in Journal of Visualized Experiments, 2025. Written by Wei Nie and 1 co-authors. Institution: Department Four of Brain Disease, Xi'an TCM Hospital of Encephalopathy. Major MEDLINE topics: Levodopa, Neuroprotective Agents, Drugs, Chinese Herbal, Parkinson Disease. Cited 1 times so far (Crossref); 56 references.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Parkinson's disease (PD) is a complex neurological disorder that causes debilitating motor symptoms such as tremors, rigidity, and bradykinesia. TCM formulations, such as Zhengan Xifeng Decoction (ZXFD) in combination with Western medicine (Levodopa), are being examined for Parkinson's disease treatment. However, the absence of reliable and interpretable experimental models has hampered mechanism elucidation. This study evaluated the neuroprotective effects of ZXFD in a rat model of PD, assessing its efficacy and safety when combined with Western medicine (WM). 240 mice with MPTP-induced PD-like symptoms were separated into two groups: the intervention group (IG, n = 120) got ZXFD + levodopa, and the control group (CG, n = 120) received only levodopa. Rotarod, open field, raised maze, Morris water maze, and tail suspension tests assessed motor function and cognitive performance after 12 weeks of therapy. Secondary outcome variables included ZXFD-Levodopa pharmacokinetic interactions and adverse event characteristics. Both treatment methods increase mouse motor function and cognitive functioning, as seen by improved scores on all behavioral tests. However, the ZXFD+ Levodopa group improved more significantly. Rotarod, Open Field, Morris water maze, and tail suspension scores improved significantly. We found significant ZXFD-Levodopa pharmacokinetic interactions in both groups. In the CG, Cmax was 150.9 ± 35.6 ng/mL, Tmax was 1.8 ± 0.5 h, AUC0-∞ was 654.2 ± 153.9 ng.h/mL, clearance was 23.4 ± 5.6 L/h, and half-life was 4.2 ± 1.0 h. In contrast, the IG showed a Cmax of 421.9 ± 93.5 ng/mL, Tmax of 3.2 ± 1.1 h, AUC0-∞ of 2431.9 ± 561.2 ng.h/mL, and clearance of 10.3 L/h, with reduced adverse events and mortality. According to this study, ZXFD + Levodopa could be a safe and effective treatment for Parkinson's disease-like symptoms. These findings indicate that this combined therapy strategy requires more clinical investigation to prove its efficacy and safety.

Subjects

MeSH terms (MEDLINE)

LevodopaNeuroprotective AgentsDrugs, Chinese HerbalParkinson DiseaseMedicine, Chinese TraditionalAnimalsMiceMaleRatsBehavior, AnimalMice, Inbred C57BLDrug SynergismAntiparkinson AgentsRats, Sprague-Dawley

Substances

LevodopaNeuroprotective AgentsDrugs, Chinese HerbalAntiparkinson Agents

Authors and institutions

  • Department Four of Brain Disease, Xi'an TCM Hospital of Encephalopathy.
  • Department Two of Internal Medicine, Xi'an TCM Hospital of Encephalopathy; wyzllwjm501@outlook.com.

Cite

APA

Nie, W., & Li, L. (2025). Synergistic Neuroprotective Effects of Traditional Chinese Medicine and Levodopa in Parkinson's Disease: A Behavioral and Pharmacokinetic Study. Journal of Visualized Experiments. https://doi.org/10.3791/69260

Vancouver

Nie W, Li L. Synergistic Neuroprotective Effects of Traditional Chinese Medicine and Levodopa in Parkinson's Disease: A Behavioral and Pharmacokinetic Study. Journal of Visualized Experiments. 2025. doi:10.3791/69260

BibTeX
@article{Nie2025,
  author = {Nie, Wei and Li, Ling},
  title = {Synergistic Neuroprotective Effects of Traditional Chinese Medicine and Levodopa in Parkinson's Disease: A Behavioral and Pharmacokinetic Study},
  journal = {Journal of Visualized Experiments},
  year = {2025},
  doi = {10.3791/69260}
}
Start for free →